Clinical Trial Update: CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating CD79b-19 CAR T cells for relapsed or refractory non-Hodgkin lymphoma, including several subtypes, is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Grade 3b Follicular Lymphoma
• High-grade B-cell Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Mediastinal Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• CD79b-19 CAR T Cells

Snippet

Sponsor: Marcela V. Maus, M.D.,Ph.D. | Conditions: Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 1 | Status: RECRUITING